TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00030693

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox-B7.1 vaccine
Description: Given intratumorally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox-TRICOM vaccine
Description: Given intratumorally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT03379077

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LTP Plus
Description: LTP Plus is comprised of two components; Learning through play (LTP) and Cognitive Behavior Therapy (CBT). The LTP Plus is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LTP Plus
Description: LTP Plus is comprised of two components; Learning through play (LTP) and Cognitive Behavior Therapy (CBT). The LTP Plus is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
Study: NCT02419313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: incobotulinumtoxinA
Description: Subjects randomized to the active drug intervention arm will receive incobotulinumtoxinA (Xeomin). A series of rating scales and examinations will take place prior to treatment and for 24 weeks after treatment. At 12 weeks the subjects will cross over to the placebo (saline) arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: incobotulinumtoxinA
Description: Subjects randomized to the active drug intervention arm will receive incobotulinumtoxinA (Xeomin). A series of rating scales and examinations will take place prior to treatment and for 24 weeks after treatment. At 12 weeks the subjects will cross over to the placebo (saline) arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: same volume as injected for incobotulinum toxin A into forearm muscles under EMG guidance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: same volume as injected for incobotulinum toxin A into forearm muscles under EMG guidance.
Study: NCT05271539

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis alone group
Description: The Lucentis alone group received 3 monthly intravitreal injections of lucentis alone or less than 3 injections if the central foveal thickness reached 250 microns

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis dexamethasone group
Description: Lucentis dexamethasone group received intravitreal injections of combination of both lucentis and commercial dexamethasone. the second group received monthly intravitreal injections of the same dose of ranibizumab combined with 0.4 mg in 0.1 ml dexamethasone (Dexamethasone sodium phosphate, Amriya Pharmaceuticals, Cairo, Egypt) in a separate 1ml syringe with 27- gauge × ½ inch sterile injection needle, followed by 2 Intravitreal ranibizumab, 1 month apart (with dexamethasone if follow up OCT shows less than 10% improvement from baseline i.e., PRN). Treatment was stopped when CMT improved below 250 µ.
Study: NCT03833596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: All 3 arms will receive Prednisone - 2 will be standard course treatment, 1 will be short course and rapidly-tapered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: All 3 arms will receive Prednisone - 2 will be standard course treatment, 1 will be short course and rapidly-tapered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: All 3 arms will receive Prednisone - 2 will be standard course treatment, 1 will be short course and rapidly-tapered

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Exclusive Enteral Nutrition
Description: 2 arms will receive EEN, in concurrence with either regular-course or short course and rapidly-tapered CS.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Exclusive Enteral Nutrition
Description: 2 arms will receive EEN, in concurrence with either regular-course or short course and rapidly-tapered CS.
Study: NCT03308110

Intervention type: DRUG
Group type: OTHER
Intervention: PF-06650833
Description: Two formulations of PF-006650833
Study: NCT01319682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous lidocaine injection
Description: Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous normal saline injection
Description: The patients in Group C (placebo control group) received normal saline intravenous injection
Study: NCT02739789

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: tDCS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham tDCS
Study: NCT01514539

Intervention type: OTHER
Group type: OTHER
Intervention: cross-sectional
Description: Monitoring two recently discovered appetite hormones called ghrelin and neuropeptide YY (PYY). This study evaluated whether fasting or postprandial ghrelin or PYY is different btween lactating and nonlactating postpartum women matched for age, body weight, and adiposity.

Intervention type: OTHER
Group type: OTHER
Intervention: cross-sectional
Description: Monitoring two recently discovered appetite hormones called ghrelin and neuropeptide YY (PYY). This study evaluated whether fasting or postprandial ghrelin or PYY is different btween lactating and nonlactating postpartum women matched for age, body weight, and adiposity.
Study: NCT04439448

Intervention type: RADIATION
Intervention: dual-energy X-ray absorptiometry (DEXA) scan
Description: Whole body dual-energy X-ray absorptiometry (DEXA) scan to assess lean and fat mass

Intervention type: RADIATION
Intervention: dual-energy X-ray absorptiometry (DEXA) scan
Description: Whole body dual-energy X-ray absorptiometry (DEXA) scan to assess lean and fat mass

Intervention type: RADIATION
Intervention: dual-energy X-ray absorptiometry (DEXA) scan
Description: Whole body dual-energy X-ray absorptiometry (DEXA) scan to assess lean and fat mass

Intervention type: OTHER
Intervention: Carotid and branchial artery ultrasound
Description: Ultrasound to assess carotid plaque and brachial artery flow mediated dilation

Intervention type: OTHER
Intervention: Carotid and branchial artery ultrasound
Description: Ultrasound to assess carotid plaque and brachial artery flow mediated dilation

Intervention type: OTHER
Intervention: Carotid and branchial artery ultrasound
Description: Ultrasound to assess carotid plaque and brachial artery flow mediated dilation

Intervention type: DIAGNOSTIC_TEST
Intervention: 2-hour oral glucose tolerace test
Description: Ingestion of 75g of glucose syrup with blood collection for glucose and insulin at time 0, 90min and 120min

Intervention type: DIAGNOSTIC_TEST
Intervention: 2-hour oral glucose tolerace test
Description: Ingestion of 75g of glucose syrup with blood collection for glucose and insulin at time 0, 90min and 120min
Study: NCT02219126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Study: NCT00695643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine
Description: 3 g per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 g per day
Study: NCT03899753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2-Octyl Cyanoacrylate and Mesh
Description: 2-Octyl Cyanoacrylate and a mesh will be applied to final closure of wounds after undergoing a Total Shoulder Arthroplasty
Study: NCT04439448

Intervention type: DIAGNOSTIC_TEST
Intervention: 2-hour oral glucose tolerace test
Description: Ingestion of 75g of glucose syrup with blood collection for glucose and insulin at time 0, 90min and 120min

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood collection
Description: Blood collection for measurement of circulating proteins (cytokines) and isolation of immune cells

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood collection
Description: Blood collection for measurement of circulating proteins (cytokines) and isolation of immune cells

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood collection
Description: Blood collection for measurement of circulating proteins (cytokines) and isolation of immune cells
Study: NCT03899753

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2-Octyl Cyanoacrylate
Description: Incisions will be closed with 2-Octyl Cyanoacrylate after undergoing a Total shoulder arthroplasty
Study: NCT03156790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spectrila®
Description: 3 intravenous doses of 10 000 U/m² BSA each during induction phase I of the underlying BRALL 2014 treatment protocol on Days 21, 23 and 25. Additionally, the subjects (standard risk subjects only) will receive doses of 10 000 U/m² BSA each on Days 2, 4, 6, 9, 11 and 13 of the consolidation phase II, III and VI of BRALL 2014 treatment protocol.
Study: NCT04404712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]MK-3168
Description: One PET scan involving administration of PET ligand \[11C\]MK-3168
Study: NCT02308748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dofetilide
Description: * 8 am: Placebo~* 12 pm (noon): 250 µg~* 5:30 pm: 250 µg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dofetilide
Description: * 8 am: Placebo~* 12 pm (noon): 250 µg~* 5:30 pm: 250 µg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dofetilide
Description: * 8 am: Placebo~* 12 pm (noon): 250 µg~* 5:30 pm: 250 µg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mexiletine
Description: * 8 am: weight x 4 mg/kg~* 12 pm (noon): Same as at 8 am~* 5:30 pm: Same as at 8 am

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: * 9 am : 30 µg/min per kg (loading) for 60 minutes and 10 µg/min per kg (maintenance) for 30 minutes~* 2 pm: 55 µg/min per kg (loading) for 60 minutes and 20 µg/min per kg (maintenance) for 30 minutes~* 7:30 pm: 52 µg/min per kg (loading) for 60 minutes and 20 µg/min per kg (maintenance) for 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: * 9 am: 5.63 mg/h per kg (loading) for 1 hour and 0.26 mg/h per kg (maintenance for 30 minutes)~* 2 pm: 6.14 mg/h per kg (loading) for 1 hour and 0.49 mg/h per kg (maintenance for 30 minutes)~* 7:30 pm: 2.23 mg/h per kg (loading) for 1 hour and 0.49 mg/h per kg (maintenance for 30 minutes)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem
Description: • 7:30 pm: 330 µg/h per kg (loading) for 60 minutes and 61 µg/h per kg (maintenance) for 30 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (#2 Gelcap or IV saline)
Study: NCT03364751

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IQOS
Description: Patients will switch from cigarette smoking to ad libitum IQOS use.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cigarette
Description: Patients will continue to smoke cigarettes ad libitum.
Study: NCT04097457

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent training for disruptive behaviors manual (Bearss, Johnson, Handen, Butter, Lecavalier, Smith & Scahill, 2018)
Description: The intervention is a short term parent training program based on behavioral principles, which can be delivered by trained therapist. The manual includes eleven core sessions, home visit session, follow-up telephone booster sessions and seven supplemental sessions, designed to be delivered individually to parents in an outpatient setting.~The protocol will be administered to groups of 3-4 parents, with a quantitative pretest-post test design evaluated at five time points, including a follow up at one month post intervention. The protocol will be administered in various community and educational locations, such as schools and community centers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent training for disruptive behaviors manual (Bearss, Johnson, Handen, Butter, Lecavalier, Smith & Scahill, 2018)
Description: The intervention is a short term parent training program based on behavioral principles, which can be delivered by trained therapist. The manual includes eleven core sessions, home visit session, follow-up telephone booster sessions and seven supplemental sessions, designed to be delivered individually to parents in an outpatient setting.~The protocol will be administered to groups of 3-4 parents, with a quantitative pretest-post test design evaluated at five time points, including a follow up at one month post intervention. The protocol will be administered in various community and educational locations, such as schools and community centers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent training for disruptive behaviors manual (Bearss, Johnson, Handen, Butter, Lecavalier, Smith & Scahill, 2018)
Description: The intervention is a short term parent training program based on behavioral principles, which can be delivered by trained therapist. The manual includes eleven core sessions, home visit session, follow-up telephone booster sessions and seven supplemental sessions, designed to be delivered individually to parents in an outpatient setting.~The protocol will be administered to groups of 3-4 parents, with a quantitative pretest-post test design evaluated at five time points, including a follow up at one month post intervention. The protocol will be administered in various community and educational locations, such as schools and community centers
Study: NCT01869010

Intervention type: OTHER
Intervention: Low sodium water overload in HIV tenofovir, HIV no tenofovir and seronegative controls
Description: This test is based on the exploration of the tubular response to an acute fluid load. After overnight fast, all participants received twenty cc/Kg of mineralized water per os and two liters of intravenous hypotonic solution (0.66%) infused in two hours. Three blood samples are drawn (at 0, 60 and 120 minutes) and also urine samples are collected from each person at baseline and at 30 (±5) minutes intervals during the whole test. From the obtained blood and urine samples creatinine and osmolarity are measured, and then from the data corresponding to the most hypotonic urine sample (maximum dilution) and its corresponding blood sample three renal physiological parameters (proximal sodium clearance, free water clearance, sodium TALH reabsorption) are analyzed. Since patient inclusion follow up period is one month

Intervention type: OTHER
Intervention: Low sodium water overload in HIV tenofovir, HIV no tenofovir and seronegative controls
Description: This test is based on the exploration of the tubular response to an acute fluid load. After overnight fast, all participants received twenty cc/Kg of mineralized water per os and two liters of intravenous hypotonic solution (0.66%) infused in two hours. Three blood samples are drawn (at 0, 60 and 120 minutes) and also urine samples are collected from each person at baseline and at 30 (±5) minutes intervals during the whole test. From the obtained blood and urine samples creatinine and osmolarity are measured, and then from the data corresponding to the most hypotonic urine sample (maximum dilution) and its corresponding blood sample three renal physiological parameters (proximal sodium clearance, free water clearance, sodium TALH reabsorption) are analyzed. Since patient inclusion follow up period is one month

Intervention type: OTHER
Intervention: Low sodium water overload in HIV tenofovir, HIV no tenofovir and seronegative controls
Description: This test is based on the exploration of the tubular response to an acute fluid load. After overnight fast, all participants received twenty cc/Kg of mineralized water per os and two liters of intravenous hypotonic solution (0.66%) infused in two hours. Three blood samples are drawn (at 0, 60 and 120 minutes) and also urine samples are collected from each person at baseline and at 30 (±5) minutes intervals during the whole test. From the obtained blood and urine samples creatinine and osmolarity are measured, and then from the data corresponding to the most hypotonic urine sample (maximum dilution) and its corresponding blood sample three renal physiological parameters (proximal sodium clearance, free water clearance, sodium TALH reabsorption) are analyzed. Since patient inclusion follow up period is one month
Study: NCT02413580

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGIV-C
Description: An IV dose of 2 g/kg of IGIV-C was administered over 2 consecutive days at a dose of 1 g/kg per day.
Study: NCT01072461

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HAS Training
Description: Robotically measured and facilitated training of the hemiparetic hand and arm in isolation, in a three dimensional haptically rendered virtual environment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HAT training
Description: Robotically measured and facilitated training of the hemiparetic hand and arm as an integrated functional unit, in a three dimensional haptically rendered virtual environment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bimanual Training
Description: Robotically measured and facilitated training of the hemiparetic hand and non-hemiparetic hand together, in a three dimensional haptically rendered virtual environment
Study: NCT00850473

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Patient will have one imaging modality - a Positron Emitting Tomography CT which includes F-18 FDG and heparin/intralipid infusion and Contrast Dye.
Study: NCT01994954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RHO
Description: Recorded oximetry data will be downloaded from home oximeters, analyzed, and used to assist in supplemental oxygen weaning decisions.
Study: NCT01268748

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional laparoscopic procedure
Description: Patients allocated to this group will undergo laparoscopic cholecystectomy using two 12 mm ports and two 5 mm ports

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Experimental laparoscopic procedure
Description: Patients allocated to this group will undergo laparoscopic cholecystectomy using only a transumbilical SILS port
Study: NCT02608983

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agar H1CC2013
Description: Following a 28-day washout one 250ml drink / day containing 8g of agar H1CC2013 as part of normal diet for 28 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agar H1CC2012
Description: Following a 28-day washout one 250ml drink / day containing 8g of agar H1CC2012 as part of normal diet for 28 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Following a 28-day washout one 250ml drink / day containing 8g of maltodextrin as part of normal diet for 28 days
Study: NCT01533324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 combined with Leucovorin
Description: S-1 capsules 80mg/m2/d BID one week on and one week off Leucovorin tablets 50mg/d BID one week on and one week off
Study: NCT03820635

Intervention type: DIAGNOSTIC_TEST
Intervention: Osteopontin (OPN)
Description: the serum level of Osteopontin (OPN) will be measured in the subject's blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: Osteopontin (OPN)
Description: the serum level of Osteopontin (OPN) will be measured in the subject's blood sample
Study: NCT01544842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1 % tacrolimus ointment
Description: applied topically to oral mucosa

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1 % triamcinolone paste
Description: applied topically to oral mucosa

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Orabase paste
Description: applied topically to oral mucosa
Study: NCT02572583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liugan Shuangjie Heji

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Shufeng Jiedu Capsule
Study: NCT02942108

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: piezo surgery
Study: NCT02572583

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir Phosphate Capsule
Study: NCT02942108

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Study: NCT00624156

Intervention type: BEHAVIORAL
Intervention: Writing Intervention
Description: Participants in the emotional disclosure condition will be instructed to write continuously for 20 minutes about their deepest thoughts and feelings regarding their cancer experience.

Intervention type: BEHAVIORAL
Intervention: Writing Intervention
Description: Participants assigned to the control condition will be instructed to describe in a detailed, nonemotional manner their daily activities. The 20-minute writing task will be introduced as a time management intervention
Study: NCT02515279

Intervention type: DRUG
Intervention: Peginterferon alfa-2a
Description: 180 micrograms subcutaneous weekly for 48 weeks.

Intervention type: DRUG
Intervention: Ribavirin
Description: 1000-1600 mg day orally for 48 weeks.
Study: NCT04640532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232, administered by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232, administered by mouth
Study: NCT03532386

Intervention type: PROCEDURE
Intervention: ICSI
Description: ICSI for both couples